(Circulation. 1999;99:2717-2719.)
© 1999 American Heart Association, Inc.
Brief Rapid Communications |
Stromelysin Promoter 5A/6A Polymorphism Is Associated With Acute Myocardial Infarction
From the First Department of Internal Medicine, Kobe University School of Medicine, Kobe, and Himeji Cardiovascular Center, Hyogo (H.K., Y.Y.), Japan.
Correspondence to Hozuka Akita, the First Department of Internal Medicine, Kobe University School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, Japan 650-0017. E-mail ahozu{at}med.kobe-u.ac.jp
Background—Rupture of the fibrous cap of an atherosclerotic plaque is a key event that predisposes to acute myocardial infarction (AMI). Matrix metalloproteinases (MMPs) may contribute to weakening of the cap, which favors rupture. Stromelysin, a member of MMP family, is identified extensively in human coronary atherosclerotic lesions. It can degrade most of the constituents of extracellular matrix as well as activating other MMPs, which suggests that it may play an important role in plaque rupture. Recently, a common variant (5A/6A) in the promoter of the stromelysin gene has been identified. The 5A/6A polymorphism could regulate the transcription of the stromelysin gene in an allele-specific manner.
Methods and Results—To investigate the relation between the 5A/6A polymorphism in the promoter of the stromelysin gene and AMI, we conducted a case-control study of 330 AMI patients and 330 control subjects. The prevalence of the 5A/6A+5A/5A genotype was significantly more frequent in the patients with AMI than in control subjects (48.8% vs 32.7%, P<0.0001). In logistic regression models, the odds ratio of the 5A/6A+5A/5A was 2.25 (95% CI, 1.51 to 3.35). The association of 5A/6A polymorphism with AMI was statistically significant and independent of other risk factors.
Conclusions—The 5A/6A polymorphism in the promoter of the stromelysin gene is a novel pathogenetic risk factor for AMI.
Key Words: plaque • metalloproteinases • myocardial infarction • risk factors
This article has been cited by other articles:
 |
|
 |
|
  C. Monaco, S. M. Gregan, T. J. Navin, B. M.J. Foxwell, A. H. Davies, and M. Feldmann Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis Circulation, December 15, 2009; 120(24): 2462 - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat Matrix Metalloproteinase-8 and the Regulation of Blood Pressure, Vascular Inflammation, and Atherosclerotic Lesion Growth Circ. Res., October 23, 2009; 105(9): 827 - 829. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cozzolino, M. L. Biondi, A. Galassi, O. Turri, D. Brancaccio, and M. Gallieni Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2207 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pons, F. R. de Vries, P. J. van den Elsen, B. T. Heijmans, P. H.A. Quax, and J. W. Jukema Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease Eur. Heart J., February 1, 2009; 30(3): 266 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Oceandy, R. Yusoff, F. M. Baudoin, L. Neyses, and S. G. Ray Promoter polymorphism of the matrix metalloproteinase 3 gene is associated with regurgitation and left ventricular remodelling in mitral valve prolapse patients Eur J Heart Fail, October 1, 2007; 9(10): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. White, S. J. Duffy, A. S. Walton, J. F. Ng, G. E. Rice, S. Mukherjee, J. A. Shaw, G. L. Jennings, A. M. Dart, and B. A. Kingwell Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease Cardiovasc Res, September 1, 2007; 75(4): 813 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barlic and P. M. Murphy Chemokine regulation of atherosclerosis J. Leukoc. Biol., August 1, 2007; 82(2): 226 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Dollery and P. Libby Atherosclerosis and proteinase activation Cardiovasc Res, February 15, 2006; 69(3): 625 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome Cardiovasc Res, February 15, 2006; 69(3): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Newby and J. L. Johnson Genetic Strategies to Elucidate the Roles of Matrix Metalloproteinases in Atherosclerotic Plaque Growth and Stability Circ. Res., November 11, 2005; 97(10): 958 - 960. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jin, M. Weisman, G. Zhang, M. Ward, J. Luo, J. Bruckel, R. Inman, M. A. Khan, H. R. Schumacher, W. P. Maksymowych, et al. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity Rheumatology, January 1, 2005; 44(1): 55 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Flex, E. Gaetani, P. Papaleo, G. Straface, A. S. Proia, G. Pecorini, P. Tondi, P. Pola, and R. Pola Proinflammatory Genetic Profiles in Subjects With History of Ischemic Stroke Stroke, October 1, 2004; 35(10): 2270 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L F Pender, P J P Croucher, S Mascheretti, J D Prothero, S A Fisher, T T MacDonald, S Schreiber, and S. Ye Transmission disequilibrium test of stromelysin-1 gene variation in relation to Crohn's disease J. Med. Genet., September 1, 2004; 41(9): e112 - e112. [Full Text] [PDF]
|
|
|
|
|
|
G. H. Gibbons, C. C. Liew, M. O. Goodarzi, J. I. Rotter, W. A. Hsueh, H. M. Siragy, R. Pratt, and V. J. Dzau Genetic Markers: Progress and Potential for Cardiovascular Disease Circulation, June 29, 2004; 109(25_suppl_1): IV-47 - IV-58. [Full Text] [PDF]
|
|
|
|
|
|
Y. Murase, Y. Yamada, A. Hirashiki, S. Ichihara, H. Kanda, M. Watarai, F. Takatsu, T. Murohara, and M. Yokota Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women Eur. Heart J., June 1, 2004; 25(11): 970 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-L. Eriksson, S. Skrtic, A. Niklason, L. M. Hulten, O. Wiklund, T. Hedner, and C. Ohlsson Association between the low activity genotype of catechol-O-methyltransferase and myocardial infarction in a hypertensive population Eur. Heart J., March 1, 2004; 25(5): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B Jones, D. C Sane, and D. M Herrington Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome Cardiovasc Res, October 1, 2003; 59(4): 812 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Beyzade, S. Zhang, Y.-k. Wong, I. N. M. Day, P. Eriksson, and S. Ye Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Medley, B. A. Kingwell, C. D. Gatzka, P. Pillay, and T. J. Cole Matrix Metalloproteinase-3 Genotype Contributes to Age-Related Aortic Stiffening Through Modulation of Gene and Protein Expression Circ. Res., June 13, 2003; 92(11): 1254 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lamblin, C. Bauters, X. Hermant, J.-M. Lablanche, N. Helbecque, and P. Amouyel Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease J. Am. Coll. Cardiol., July 3, 2002; 40(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.B. Taegtmeyer and P.J.R. Barton SNP at your own risk Eur. Heart J., May 1, 2002; 23(9): 692 - 694. [Full Text] [PDF]
|
|
|
|
|
|
S. Humphries, C. Bauters, A. Meirhaeghe, L. Luong, M. Bertrand, and P. Amouyel The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis Eur. Heart J., May 1, 2002; 23(9): 721 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]
|
|
|
|
|
|
W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF]
|
|
|
|
|
|
B. Zhang, S. Dhillon, I. Geary, W. M. Howell, F. Iannotti, I. N.M. Day, and S. Ye Polymorphisms in Matrix Metalloproteinase-1, -3, -9, and -12 Genes in Relation to Subarachnoid Hemorrhage Stroke, September 1, 2001; 32(9): 2198 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gnasso, C. Motti, C. Irace, C. Carallo, L. Liberatoscioli, S. Bernardini, R. Massoud, P. L. Mattioli, G. Federici, and C. Cortese Genetic Variation in Human Stromelysin Gene Promoter and Common Carotid Geometry in Healthy Male Subjects Arterioscler Thromb Vasc Biol, June 1, 2000; 20(6): 1600 - 1605. [Abstract] [Full Text] [PDF]
|
|